

Index

a

- acetylation, effect on chitosan transfection efficiency 79–80
- acroinfundibulum 354
- active compound penetration, skin 365
- active drug targeting 163–164
- active pharmaceutical ingredients (API) 255
 - carriers 258
- active targeting 289
- adhesive capacity, gliadin nanoparticles 133
- adhesive interactions, gliadin nanoparticles 130
- adsorption, association of ligands with nanoparticles 127
- adsorption equilibrium 130
- AFM *see* atomic force microscopy
- agarose gel electrophoresis
- (C₁₄CO)₂–plasmid complexes 35
- DNA anchor 44–45
- aggregation
 - lipoplexes 57
 - modified chitosans 80
- aggregation concentration, critical 35–36
- albumin
 - clinical indication 185
 - nanoparticle preparation 154
 - principal function 187
- albumin microspheres 151
 - hormone-containing 175
- albumin nanoparticles 185–218
 - biodistribution 196–198
 - carrier system 173
 - chemical stabilization 195
 - conventional 187–193
 - diagnostic purposes 198–200
 - distribution 199–201
 - drug encapsulation 194–196
 - emulsification 192–193
 - immunochemical detection 207
 - magnetic 204
 - ocular drug delivery 205–207
 - preparation 187, 189–193
 - protective effect 201
 - Scanning electron microscope image 188
 - surface-modified 193–196
 - three-step procedure 190
 - toxicity 206
- Albunex 173
 - immune response 176
- alkyl cyanoacrylate nanocapsules 381–382
- all-*trans* retinoic acid (RA) 124–125
- amino acid microspheres 382
- amino groups
 - interaction of chitosan amino group with DNA 75
 - N-chitosan 72
 - trimethylation (quaternization) 80
- γ-aminobutyric acid (GABA) 358
- amphiphilic drug encapsulation 126–127
- antibody, variable domain of the light chain 235
- antibody response, nanoparticle preparation 170
- anticancer agent, mercaptopurine 149
- antiepileptic drug delivery 366–367
- antimucous polyclonal antibodies 166
- antineoplastic agents 369
- antisense oligonucleotides 199–201
- API *see* active pharmaceutical ingredients
- apoE *see* apolipoprotein E
- apolipoprotein E, enrichment 291
- array structure, DNA nanotubes 10
- artificial lipid vesicles, liposomes 239
- ASGP-R *see* asialoglycoprotein receptor
- asialoglycoprotein receptor (ASGP-R) 81–82
- atomic force microscopy (AFM)
 - chitosan–DNA complexes 75
 - DNA nanotubes 7, 12–14

- atovaquone 383
 azidothymidine (AZT) 157
 AZT *see* azidothymidine
- b**
- B16-F10 cells
 – fluorescence microscopic images 333
 – viability 334
 BALB/c mice 96
 ball milling 265
 BBB, crossing 357
 BBD *see* *Bordetella bronchiseptica* dermonecrotin
 benzalkonium chloride (BZC), amphiphilic model 126–127
 betamethasone disodium phosphate (BTM), included in chitosan microspheres 89
 bifunctional crosslinkers 168
 – structure 169
 bilayer undulations, lamellar lipoplexes 55–56
 bioadhesion 129
 bioadhesive properties, gliadin nanoparticles 129–135
 bioavailability, drug particle size dependence 256
 biocompatibility, chitosan 71
 biocompatible nanoparticulate systems for tumor diagnosis 304–348
 biodegradable, plant protein-based nanoparticles 117
 biodegradable nanoparticles 312–314
 biodegradable polymer, delivery to BBB 373–374
 biodegradation, chitosan 71
 biodistribution
 – albumin nanoparticles 196
 – in vivo 26–27
 biofunctionalized solid lipid nanoparticles, production 287–303
 biological membranes
 – asymmetry 353
 – crossing by nanoparticles 349–393
 – drugs crossing problems 354–362
 – functions 351–352
 – kinetics 352–354
 – lipid bilayer structure 260
 – thermodynamics 352–354
 – *see also* cell membrane
 biomembranes *see* biological membranes
 bionanomachines 19
 1,6-bis-maleinimido-hexane (BMH) 168
 blood circulation time, ICG 325
 blood opsonization process, reduction 287
 blood–brain barrier
 – crossing of albumin nanoparticles 197
 – diffusion of nanoparticles 305
 bloodstream, surviving of chitosan–DNA nanoparticles 80
 BMH *see* 1,6-bis-maleinimido-hexane
 body distribution
 – drug carrier systems 163
 – peroral administration 175
Bordetella bronchiseptica dermonecrotin (BBD) 87
 bovine serum albumin *see* BSA
 breast cancer 370
 bromocriptine mesylate, drug-loaded gelatin microspheres 152
 BSA (bovine serum albumin) 187
 – incorporated in hydrophobic PLGA microspheres 148
 – nanoencapsulation 153
 – release from chitosan nanoparticles 95
 BTM *see* betamethasone disodium phosphate
 buckyballs 307–309
 buckytubes 307–309
 building blocks, nanoscale particulate systems 305–312
 burst effect, in chitosan microsphere DNA release 95
 2,3-butadione, albumin nanoparticles chemical stabilization 189
 BZC *see* benzalkonium chloride
- c**
- C₁₀CysG+ 29–30
 – structure 31, 34
 C₁₄CO, structure 34
 C₁₄CSper, structure 34
 (C₁₄CO)₂–plasmid complexes, mobility 35
 cancer treatment, albumin nanoparticles 201–204
 capillary endothelial cells, lipoplex uptake 60
 carbazole, hydrophobic fluorescent molecule 130–132, 134
 carbodiimide (CDI)
 – crosslinked with gliadin nanoparticles 133
 – preparation of ligand–gliadin nanoparticle conjugates 128
 carbohydrate-binding, S-layer 223–224
 carbon nanotubes 308
 carcinogenic radicals 288
 carriers
 – albumin nanoparticles 199
 – DNA 69–79
 cationic lipid-mediated nucleic acid delivery *see* lipofection

- cationic lipids 51–53
- cationic liposomes, interactions with DNA 56
- cationic surfactants, structure 34
- caveolae-mediated endocytosis 58
- CDI *see* carbodiimide
- cell internalization elements, DNA nanoparticles 43–46
- cell-mediated response, legumin nanoparticles 137
- cell membrane 350–354
 - fusion with lipoplexes 57
 - *see also* biological membranes
- cell membrane crossing, DNA-nanoparticles 77
- cell recognition, DNA nanoparticles 43–47
- cell surface receptors, mediation of gene carrier targeting 81–83
- cellular trafficking studies 38
- CFTR *see* cystic fibrosis transport regulator
- cGMP *see* pharmaceutical current good manufacturing practice
- charge density, effect on chitosan transfection efficiency 79–80
- chemical crosslinking, chitosan nanoparticle preparation 86
- chimeric proteins 43
- chitin 68
 - structure 69
- chitosan 258
 - *N*-dodecylated chitosan (CS-12) 83–84
 - biocompatibility 71
 - carrier for gene therapy 69–79
 - chemistry 69–71
 - deoxycholic acid-modified chitosan (DAMC) 84
 - DNA–chitosan nanoparticles 68–99
 - galactosylated chitosan (GC) 81–82
 - GCPVP 81
 - genipin-crosslinked microspheres 88
 - heparin–chitosan complex 90
 - hydrophobic modification 83–84
 - pK_a 70
 - proposed applications 74
 - schematic gene therapy mechanism 79
 - structure 69
 - *see also* modified chitosan, unmodified chitosan
- chitosan nanoparticles
 - chemical crosslinking 86
 - complex coacervation 84–86
 - DNA loading 91–93
 - DNA release and release kinetics 93–95
 - emulsion crosslinking 87–88
 - emulsion droplet coalescence 90
 - ionic crosslinking/gelation 86–87
 - preparation methods 84–91
 - release of bovine serum albumin 95
 - reverse micellar method 89
 - sieving method 91
 - spray drying 88–89
- chitosan–DNA complex
 - atomic force microscopy (AFM) 75
 - incorporation by inhaled powder 98
 - potential clinical applications 97–98
 - preclinical evidence of efficacy 95–97
 - therapy of respiratory syncytial virus infection 97
- chitosan–DNA interactions 71
- cholester, structure 53
- circular dichroism (CD) measurements, S-layers 221
- circumventricular organs (CVO) 358
- clathrin-mediated endocytosis 58
- clinical studies, protein-based particles 172
- clinical uses, ICG 320–321
- coacervation, albumin nanoparticles 187, 189–192
 - nanoparticle preparation 120, 154–159
- coacervation techniques
 - complex 154–155
 - simple 155–159
- cochleate cylinders 265
- cochleates, lipid 263
- colloidal carriers 117
- colloidal drug carriers 287
- comminution
 - pharmaceutical nanoparticle processing 265–266
 - wet 266–267
- compaction, of DNA by highly charged chitosan 76
- complex coacervation, chitosan nanoparticle preparation 84–86
- condensation, DNA polymer 27–28
- condensed lamellar phase, lipoplexes 52–54
- conductivity, self-assembled 1-D nanotubes 18
- confocal microscopy, nanoparticle internalization 46
- connexin proteins, gap junctions 351
- connexon hexamers, gap junctions 351
- contrast enhancement, gas-filled microspheres 173
- convergent growth method, dendrimer synthesis 306
- copolymer grafted HSA 165
- core dendrimer 307
- core/shell nanoparticles 278

- cosmetic compounds, controlled release 365–366
- covalent linkage, association of ligands with nanoparticles 127
- coxsackievirus B3 (CVB3) 97–98
- CP *see* critical point
- Cremonophor 202
- Cremonophor EL 173, 368
- Crick, F. H. C. 23
- critical aggregation concentration 35–36
- critical point (CP) 270
- Crohn's disease 361
- crosslinkage, protein nanoparticles 122
- crosslinking, HSA (Human serum albumin) 150
- crosslinking agent, tripolyphosphate 258
- crustaceans 69
- crystalline bacterial cell surface layer *see* S-layer
- crystalline phases, liquid 260–261
- CS-12 (*N*-dodecylated chitosan) 83–84
- CTAB 36
- structure 34
- cubosomes 262–263
- curvature elastic energy, lipids 259–260
- CVB3 *see* coxsackievirus B3
- CVO *see* circumventricular organs
- Cybesin 325
- cyclosporin 382
- cystic fibrosis transport regulator (CFTR) 171
- Cytate 325
- cytokine, secretion in presence of nanoparticles 73
- cytotoxicity
- chitosan–DNA nanoparticles 99
- decrease 156
- galactosylated chitosan (GC) 82
- ICG 323–324
- photosensitizer molecule 319
- d**
- DAE, DNA structure 4–10
- Dalargin 372
- DAMC *see* deoxycholic acid-modified chitosan
- DAO, DNA structure 4, 9–10
- daunorubicin, hydrophilic drug 150
- DBA *see Dolichus biflorus* lectin
- DBA-gliadin nanoparticle conjugates 131
- DC-Chol, structure 53
- DDC *see* dideoxycytidine
- deacetylation, in chitosan production 69
- DEET (*N,N*-diethyl-4methyl benzamide) 365
- dendrimers 305–307, 362
- synthesis 306
- deoxycholic acid-modified chitosan (DAMC) 84
- derivatives
- *N*-chitosan *see* *N*-chitosan derivatives
- *O*-chitosan *see* *O*-chitosan derivatives
- PEG *see* PEG derivatives
- derivatized amino acid microspheres 382
- Dervan, Peter 39
- desolvation 155–159
- albumin nanoparticles 189–192
- gliadin nanoparticles 122
- protein nanoparticles 121
- detergent, C₁₀CysG+ 29–31, 36
- C₁₄CO 33, 36, 45
- cationic 27–29, 33
- lipid-based 44
- dextranox-MPEG *see* methyl polyethylene glycol (PEG)-modified oxidized dextran
- diagnostics
- albumin nanoparticles 198–200
- protein-based nanoparticles 169–175
- dideoxycytidine (ddC) 157
- diethylenetriaminepentaacetic acid (DTPA) 206
- differential adsorption 289–292
- differential scanning calorimetry 371
- direct microinjection
- lipoplexes 59
- ODN lipoplexes 62
- distamycin 38
- anchorage in minor groove 44
- disuccinimidyl tartrate (DST) 168
- disulfide bond, peptide conjugation 373–374
- DMRIE, structure 53
- DNA
- carriers 199
- chemical structure 24
- interactions with chitosan 71
- interactions with cationic liposomes 56
- interactions with fusion proteins 42–43
- DNA anchor 1, structure 44
- DNA based nanomaterials 1–99
- DNA binding intercalator 39
- DNA compaction, by highly charged chitosan 76
- DNA functionalization 37–43
- strategies 37–38
- DNA lipoplexes 51–60
- DNA loading, in chitosan micro- and nanoparticles 91–93
- DNA nanoparticles 43–47
- transfection efficiency 46
- DNA nanotubes, persistence length and stiffness 8

- DNA plasmid, size in comparison to virus and cell 27
- DNA polymer, condensation 27–28
- DNA recognition
 - by molecules 38
 - major groove 40
 - minor groove 43
- DNA release, burst effect 95
- DNA–chitosan nanoparticles 93–95
 - gene therapy 68–99
- DNA–transferrin conjugate complexes 39
- N*-dodecylated chitosan (CS-12) 83–84
- Dolichus biflorus* lectin (DBA) 128
- DOPC, structure 53
- DOPE 28, 47
 - structure 53
- DOSPA, structure 53
- DOTAP, structure 53
- DOTAP/DOPC/DNA lipoplex 56
- DOTAP/ODN lipoplex, Cryo-TEM 61
- DOTAP–DNA lipoplexes 80
- Doxil 258
- doxorubicin 368–369
 - drug carrier system 153
- droplet size, electrical field 275–277
- drug binding, in drug carrier systems 146
- drug candidates, investigations. 255
- drug carrier systems, drug binding in 146
- drug carriers
 - colloidal 287
 - doxorubicin 153
 - protein-based nanoparticles 169–175
- drug delivery 205–207
 - anticancer 367–370
 - antiepileptic 366–367
 - nanoparticulate 367
 - peptide 360
 - solid lipid nanoparticles 287–303
 - topical 205
- drug delivery systems, lipid-based 258
- drug encapsulation
 - albumin nanoparticles 194–196
 - characteristics in gliadin nanoparticles 127
 - in plant protein nanoparticles 124–127
- drug nanoparticles
 - preparation 255–286
 - structures 257
- drug particles, mean size 267
- drug targeting
 - active 163–164
 - nanoparticles 161–169
 - passive 163
- drug-targeting ligands, surface modification 166
- drugloading efficiency, albumin nanoparticles 194
- drugs crossing biological membranes, problems 354–362
- DSC 371
- DST *see* disuccinimidyl tartrate
- DTPA *see* diethylenetriaminepentaacetic acid
- DUV, deep ultraviolet light 241
- DX tile nanotubes 4–10
- dye, encapsulated 315
- dysopsonins 290, 296
- e**
- ECF 358
- echo-contrast agents, albumin nanoparticles 199
- EDC *see* 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
- EGF *see* epidermal growth factor
- EGFP *see* enhanced green fluorescent protein
- electrical field, droplet size 275
- electroless chemical deposition 18
- electron micrography, heterotetramers 232
- electronic nanodevices 18
- electroporation, low-voltage 355–357
- electrospraying 277
 - coaxial 279
 - stages 276, 278
- electrostatic approaches, nanoformulation 275
- electrostatic spinning 371
- emission spectrum
 - rEGFP 240
 - rSbpA_{31a1068}/EGFP 240
- emulsification, albumin nanoparticles 187, 192–193
- emulsification-diffusion, SLN production 294
- emulsion crosslinking, chitosan nanoparticle preparation 87–88
- emulsion droplet coalescence, chitosan nanoparticle preparation 90
- emulsion technique 151–154
 - flowchart 149
 - nanoparticle preparation 148–154
- emulsions
 - drug carriers 258
 - oil-in-water-type 261
- encapsulation efficiency, chitosan nanoparticle preparation 92–93
- endocytosis
 - lipofection 57–58
 - ODN lipoplexes 62
 - receptor-mediated 38, 372

- endosomal escape, gene carriers 78
 endosomal membrane 59
 energy of bending, lipids 259
 enhanced green fluorescent protein (EGFP) 239–240
 ependymal cells, cerebral ventricles 357
 epidermal growth factor (EGF) 369
 equilibrium structure, lipoplexes 52–55
Escherichia coli 77
 EtBr *see* ethidium bromide
 ethidium bromide (EtBr) 377
 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 155
 extracellular barriers, lipofection 59
 extracellular fluid 358
 extracellular trafficking 79
- f**
- FAM-labeled strands, DNA nanotubes 7–8
 fibrous proteins, characteristics 118
 fluorescein labeled strands, DNA nanotubes 7–8
 fluorescence
 – FAM 7–8
 – YOYO 36, 46
 fluorescence excitation
 – rEGFP 240
 – rSbpA_{31a1068}/EGFP 240
 fluorescence imaging, NIR 317–318
 fluorescence microscopy, DNA nanotubes 7–8
 fluorescent molecules, carbazole 130–132
 fluorescently labeled albumin nanoparticles 197
 5-Fluorouracil 369
 Fluorouracil delivery 201–202
 folate receptor (FR) 83, 97
 folate–peg-coated nanoparticles, biomedical applications 46
 folic acid receptor 83
 formaldehyde, albumin nanoparticles chemical stabilization 189
 FR *see* folate receptor
 freeze drying, nanoparticles 269
 5-FU *see* 5-Fluorouracil
 5-FU-loaded albumin 201
 fullerenes 362
 functional domains, Binding of Molecules and Nanoparticles 242–243
 functionalization, DNA 37–43
 fusion, lipoplexes with cell membrane 57
 fusion proteins, interactions with DNA 42–43
 fusogenic peptides 47
- g**
- G *see* generation
 γ -aminobutyric acid (GABA) 358
 GABA *see* γ -aminobutyric acid
 β -galactosidase assay 77
 galactosylated chitosan (GC) 81–82
 β -Gal gene, vivo release 96
 ganciclovir (GCV) 156, 195
 – cancer treatment 203
 gap junctions 351
 gastrointestinal mucosal segments
 – *ex vivo* studies of drug carriers 130–131
 – *in vivo* studies of drug carriers 132–135
 gastrointestinal transit profile, gliadin nanoparticles 132
 GC *see* galactosylated chitosan
 GCPVP 81
 GCV *see* ganciclovir
 gel electrophoresis, agarose 35, 44–45
 gel-shift assay, SDS 230
 gelatin A, amino acid composition 152
 gelatin-based microspheres
 – drug-loaded 152
 – emulsion technique 151–153
 gelatin–DNA nanospheres 171
 gene carrier targeting, mediation by cell surface receptors 81–83
 gene carriers, endosomal escape 78
 gene delivery 369–370
 – BBB 374–375
 gene delivery system, inhaled powder 98
 gene expression 26
 – blocked by ODN 60
 gene therapy
 – DNA–chitosan nanoparticles 68–99
 – potential clinical applications of chitosan–DNA complex 97–98
 – protein-based nanoparticles 170–172
 – use of surfactants 36
 – viral vectors 51
in vivo gene transfer 88
 gene-vector complexation 79
 generation (G), dendrimers 306
 genipin-crosslinked chitosan microspheres 88
 GFP *see* green fluorescent protein
 GI Barrier 360–362
 Gibbs equation, including nanoparticles 256
 Gibbs free energy, drug particles 256
 GlcNAc, N-acetyl glucosamine 227
 gliadin, wheat proteins 120
 gliadin nanoparticles
 – *ex vivo* studies of bioadhesive properties 130–131

- gliadin nanoparticles (*cont.*)
 - *in vivo* studies of bioadhesive properties 132–135
 - adhesive interactions 130
 - bioadhesive properties 129–135
 - gastrointestinal transit profile 132
 - ligand–gliadin nanoparticle conjugates 127–129
 - particle size optimization 135–136
 - preparation 122–124
 - RA encapsulation 124–125
 - scanning electron micrograph 123
 - VE encapsulation 125–126
 - globular assembly, plasmid 30
 - globular proteins, characteristics 118
 - globulins
 - characteristics 118
 - pea seed proteins 119
 - glutaraldehyde, albumin nanoparticles
 - chemical stabilization 189
 - glutaraldehyde, crosslinking 155
 - glutelins, characteristics 118
 - gluten, wheat proteins 120
 - glutenin, wheat proteins 120
 - glycolic acid, nanoparticle preparation 313
 - glycoprotein, S-layer 219
 - gold chips 233
 - GRAS, safe substances 364
 - green fluorescent protein 42
 - guanidine hydrochloride 220
- h**
- H_{II}C-phase, lipoplexes 52–54
 - HCMV *see* Human CMV
 - head groups, lipids 259
 - heat-induced plasmid denaturation 42
 - heavy water, cytotoxicity of ICG 324
 - HEK 293 cells 78–83, 96, 170–172
 - HeLa cells 78–83, 96, 171, 240
 - Hélène, Claude 39
 - helper lipids 52–53
 - hemispherical endcaps nanotubes 308
 - heparin, nanoparticle preparation 154
 - heparin–chitosan complex, emulsion droplet coalescence 90
 - HepG2 cells 82, 88
 - herpes virus thymidine kinase (HSV-tk), cancer treatment 203
 - heterotetramers
 - functional 229
 - fusion protein 230
 - rSbpA 232, 234
 - SbsB 231
 - hexosomes 262–263
 - high-molecular-weight (HMW) chitosan 76, 92, 95
 - high-pressure homogenization (HPH), SLN production 292–294
 - Hildebrand theory, solubility parameter of gliadin 123
 - HIV-infection, potential therapy 157
 - HMW chitosan *see* high-molecular-weight chitosan
 - Hoechst 33258 38
 - anchorage in minor groove 44
 - homotetramers, streptavidin 229
 - “honeycomb” phase, lipoplexes 52–54
 - Hoogsteen base pairs 40
 - HPH *see* high-pressure homogenization
 - HSA 187
 - acid solution 155
 - copolymer grafted 165
 - ICG binding 321
 - microsphere and nanoparticle material 148
 - quantitative amino acid composition 150
 - HSA nanoparticles, morphology 161–162
 - HSA system, ammonium sulfate coacervated 156
 - HSA–PAA–PEG 194
 - HSA–PTAAC–PEG 194
 - HSV-tk *see* herpes virus thymidine kinase
 - human CMV, pathology 206
 - human rIL-2, included in chitosan microspheres 94
 - human serum albumin *see* HSA
 - humoral responses, legumin nanoparticles 136
 - hydrated lipids, liquid crystalline phases 260–261
 - hydrocarbon chains, lipids 259
 - hydrocortisone 195
 - included in chitosan microspheres 89
 - hydrophilic compounds, surface modification 164–165
 - hydrophilic drug encapsulation 126–127
 - hydrophilic pathway, skin barrier 363
 - hydrophobic, carbazole 130–132
 - hydrophobic modification, chitosan 83–84
 - hydrophobic PLGA microspheres 148
 - hydroxypropylcellulose, thickening agent 192
- i**
- ICG 304, 320
 - binding properties 321–322
 - biodistribution 335
 - blood circulation time 325
 - chemical stability in aqueous solution 330–331

- degradation 332
 - encapsulated in nanoparticles 316
 - excretion 322
 - metabolism 322
 - nanoparticle pharmacokinetics 331–336
 - nanoparticulate delivery system 327–336
 - pharmacokinetics 322
 - physicochemical properties 321
 - release profile 330
 - solution pharmacokinetics 331–336
 - stabilization *in vitro* 326
 - structure 321
 - subcellular localization 334
 - tumor imaging 322–323
 - uptake 333
 - uptake by tumors 325
 - ICG-loaded nanoparticles, photodynamic activity 335
 - ICG-loaded PLGA nanoparticles
 - manufacturing 314
 - surface views 329
 - IgC antibodies, *Camelidae* 235
 - IL-2, expression plasmid 86, 93–95
 - included in chitosan microspheres 94
 - immunization in animals, legumin nanoparticles 136–137
 - immunological reactions, protein-based microspheres 175–177
 - immunotherapy, type I allergy 239
 - in situ* synthesis, nanoparticles 244–244
 - in vivo* biodistribution 26–27
 - indocyanine green 304
 - *see also* ICG
 - inhaled powder, gene delivery system 98
 - intercalating dye, YOYO 36, 46
 - intercalation 38–39
 - intercalator, DNA binding 39
 - interfaces, lipids 260–261
 - interfacial energy, nanoparticles 257
 - interfacial tension 275
 - interferon- γ 195
 - interlayer DNA correlations, lamellar lipoplexes 55–56
 - interleukin *see also* cytokine, IL2, 239, 373
 - secretion in presence of nanoparticles 73
 - internalization
 - chitosan–DNA complexes 83–84
 - DNA nanoparticles 43–47
 - intestinal disease 361–362
 - intestinal translocation 361–362
 - intracellular trafficking 79
 - intracytoplasmic trafficking 26–27
 - intravitreal drug delivery 205–207
 - inverse hexagonal phase, lipoplexes 52–54
 - ion channel proteins 350
 - ionic crosslinking, chitosan nanoparticle preparation 86–87
 - ionic gelation, chitosan nanoparticle preparation 86–87
 - iontophoresis 356
 - Irwin's equation 267
- k**
- Katchalsky's equation 70
 - ketoprofen 87
 - kinetic approaches, nanoparticle preparation 257
 - KNOB protein 83, 96
- l**
- L-DOPA 359
 - (L_αC)-phase, lipoplexes 52–54
 - lamellar lipoplexes, formation 55
 - Langmuir adsorption, oligonucleotides 234
 - lateral stress profile, lipid monolayer 259
 - lectin-conjugated nanoparticles, oral delivery 379–380
 - legumin, pea seed proteins 119
 - legumin nanoparticles
 - cell-mediated response 137
 - humoral responses 136
 - immunization in animals 136–137
 - preparation 121–122
 - leguminoses, source of plant proteins 119
 - ligand–gliadin nanoparticle conjugates, preparation 127–129
 - light chain antibody, variable domain 235
 - linalool–linalyl acetate (LLA) 124
 - hydrophilic model 126–127
 - lipid-based pharmaceutical nanoparticles 258–259
 - lipid emulsion, oil-in-water-type 261
 - lipid nanoparticles, site-specific drug delivery 287–303
 - lipid tubules 264
 - lipids
 - cationic 51–52
 - definition 259–260
 - hydrated 260–261
 - lipofection 51
 - direct microinjection 59
 - efficiency 57–60
 - endocytosis 57–58
 - extracellular barriers 59
 - most likely mechanism 58
 - tumor tissue 60
 - *in vitro* lipofection 57–59
 - *in vivo* lipofection 59–60

- lipophilic drug encapsulation 126–127
 - lipoplexes 51–62
 - composition 51–52
 - DOTAP–DNA 80
 - equilibrium structure 52–55
 - formation 54–55
 - fusion with cell membrane 57
 - nonequilibrium structure 55–57
 - polymorphous 56
 - size 57
 - liposomes 52, 239, 261–262, 310–312
 - conventional 262
 - drug carriers 258
 - stealth 262
 - liquid crystalline phases 260–261
 - lamellar 260
 - liquid nanodispersions, drying 267–270
 - liquid solution droplet, supercritical fluids 273
 - liver cancer, magnetic treatment 204
 - living cell imaging 376–378
 - LLA *see* linalool–linalyl acetate
 - LMW chitosan *see* low-molecular weight chitosan
 - localized SPRs, living cell imaging 376
 - low-density lipoproteins receptors 372
 - low-molecular weight (LMW) chitosan 77, 82, 92
 - low-voltage electroporation, skin 355–357
 - luciferase 170
 - lymphatic oral nanoparticulate delivery 382–384
- m**
- m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester 168
 - magnetic albumin nanoparticles 204
 - major groove, DNA recognition 40
 - ManNAc, N-acetyl mannosamine 227
 - MDR *see* multi drug resistance
 - MDS *see* microsphere-based detoxification system
 - mechanical approaches 264–270
 - mechanical irritation, skin 355
 - membranes *see* biological membranes
 - mercaptopurine, anticancer agent 149
 - messenger RNA 60
 - metabolizable plant protein-based nanoparticles 117
 - metallization
 - 4 × 4 nanoribbons 18
 - TX tile nanotubes 11
 - metastable morphology, lipoplexes 55
 - metastatic breast cancer, albumin nanoparticles 202
 - Methanothermus fervidus*
 - Methotrexate delivery 201–202
 - methyl polyethylene glycol (PEG)-modified oxidized Dextran 165
 - albumin nanoparticles chemical stabilization 189
 - MexAB–OprM 377
 - MG63 cells 96
 - mica, interaction with nanotubes 7–8
 - micelle–DNA complexes, stabilized 37
 - microbeads 238
 - microcylinder, lipid 263
 - microemulsion technique, SLN production 293
 - microscopic techniques, nanoparticle size 160
 - microspheres
 - casein-based 153–154
 - gelatin-based 151–153
 - stability 153
 - uniform 151
 - microsphere-based detoxification system 237–238
 - microstructure, lipoplexes 52–55
 - microtubules, lipid 263
 - milling 265
 - minor groove
 - agents binding to 43
 - anchorage 44
 - MLV *see* multilamellar vesicles
 - MMP-9, secretion in presence of nanoparticles 73
 - modified chitosan 71
 - targeting mediated by cell surface receptors 81–83
 - transfection efficiency 79–74
 - monomolecular DNA condensation 45
 - mononuclear phagocytic system (MPS) 81
 - MPS *see* mononuclear phagocytic system
 - mucoadhesion, nanoparticles 384–385
 - multi drug resistance (MDR) proteins 360
 - reversion 367
 - multicomponent delivery vectors 47
 - multilamellar vesicles (MLV) 261
 - multiple sclerosis, pathogenesis 197
 - multiwall cylinder nanotubes (MWNT) 308
 - MWNT *see* multiwall cylinder nanotubes
- n**
- N-chitosan derivatives
 - proposed applications 74
 - structure 72
 - nanodispersions, drying 267–270
 - nanoelectronic devices 18

- nanofibers 370–371
 - nanoformulation, drug candidates 255
 - nanomaterials
 - DNA based 1–99
 - plant protein-based 117–137
 - protein-/peptide-based 115–245
 - nanoparticle crosslinkage, physico-chemical 122
 - nanoparticle optics 376–378
 - nanoparticle preparation 313–314
 - coacervation 154–159
 - mechanical energy input 264–265
 - methods 148–159
 - simple coacervation (desolvation) techniques 155–159
 - starting materials 146
 - thermodynamic approaches 257–264
 - nanoparticles
 - biodegradable 312–314
 - casein-based 153–154
 - coacervation techniques 154–155
 - crossing biological membranes 349–393
 - desolvation yield 191
 - DNA–chitosan 68–99
 - drug targeting 161–169
 - drying 268
 - gelatin-based 151–153
 - nucleic acid 23–50
 - peptide 159–161
 - peptide-based 145–176
 - pharmaceutical 258–259
 - protein-based 164
 - nanoparticulate drug delivery 362
 - anticancer 367–370
 - BBB 371–378
 - mechanisms 375
 - PLGA-based 327–336
 - skin 366
 - subcutaneous 366–367
 - nanoparticulate systems, tumor diagnosis 304
 - nanoporous barrier, semipermeable 363
 - 4 × 4 nanoribbons 18–19
 - metallization 18
 - nanoscale particulate systems, components 305–312
 - nanosensors 370
 - nanoshells 362
 - nanostructure, lipoplexes 52–55
 - nanosuspension delivery, oral 383–384
 - nanotubes (NT) 308, 362
 - self-assembled 3–22
 - nanowires 18
 - naphthalocyanine dyes, fluorescence imaging 318
 - natural self-assembly system, nanoscale
 - patterning of S-layer proteins 219–252
 - NHS-PEG3400-Ma, PEG-based crosslinker 167
 - NIR dyes 318
 - NIR fluorescence imaging 317–318
 - NLS peptide 27
 - fusion with TetR protein 43
 - NLS peptide conjugation, triple helix formation 41
 - nonbiodegradable polymer 370–371
 - nonequilibrium structure, lipoplexes 55–57
 - NPC *see* nuclear pore complexes
 - NT *see* nanotubes
 - nuclear localization signal peptide *see* NLS peptide
 - nuclear pore complexes (NPC) 26
 - nucleic acid drugs, oral route 361
 - nucleic acid nanoparticles 23–50
 - synthesis 27–31
 - nucleus, gene expression 26
- o**
- O-chitosan derivatives
 - proposed applications 74
 - structure 73
 - ocular drug delivery, albumin nanoparticles 205–207
 - ODN
 - antisense 60–61
 - monolayers 61
 - triple helix formation 39–41
 - ODN lipoplexes 60–62
 - ODN–lipid lamellar phase 61
 - oligodeoxyribonucleotides *see* ODN
 - oligomeric chitosans 75
 - oligonucleotides
 - carriers 199
 - PNAs 41
 - optical imaging 317–326
 - fluorescence-based 317
 - optical nanoparticles, biodegradable 314–316
 - oral delivery, lectin-conjugated nanoparticles 379–380
 - oral nanoparticulate delivery 378–385
 - oral nanosuspension delivery 383
 - oral route, nucleic acid drugs 361
 - oral vaccination, protein microspheres 175
 - oxidation, C₁₀CysG+ 31
- p**
- pK_a, chitosan 70
 - PACA *see* poly(alkyl cyanoacrylate)

- paclitaxel 368
- albumin nanoparticles 202–203
- carrier system 173
- PAMAM *see* poly(amidoamine) dendrimers
- parenteral application route 172–174
- parenteral lipid emulsion 258
- particle size
 - reduction 266
 - surface energy 256
 - wet comminution 266
- particle size distribution, gliadin nanoparticles 123
- particle size optimization, gliadin nanoparticles 135–136
- particle systems
 - active drug targeting 163–164
 - passive drug targeting 163
- particulate systems, nanoscale 305–312
- PASP *see* sodium polyaspartate
- passive drug targeting 163
- passive targeting 289
- patch–clamp recording technique, cell transport 351
- patterning, S-layer proteins 219–252
- PBCA 290–291
- PBCA nanoparticles, brain specificity 297
- PC *see* phosphatidylcholine
- PCF *see* polycationic ferritin
- PCS *see* photon correlation spectroscopy
- pDNA:PLL complexes, included in chitosan microspheres 93
- PDT 317–326
 - ICG 323
 - photosensitizers 320
- PE *see* phosphatidylethanolamine
- pea seed proteins 119
- PEG 28, 82–83, 262
 - lipoplex coating 60
 - nanoparticle surface modification 287
 - protective coat 44–46, 60
- PEG derivatives, surface modification 165–166
- PEG–HSA conjugates 165
- PEG–lipid conjugates, polymeric micelles 310
- pegylation, albumin nanoparticles 193
- PEI *see* polyethylenimine
- PEO *see* polyethylene oxide
- peptide-based nanomaterials 115–245
- peptide conjugation 373–374
- peptide delivery, BBB 372–373
- peptide drug delivery 360
- peptide nanoparticles
 - oral delivery 380–381
 - polymer-based 381
- peptide nanoparticles 145–176
 - characterization techniques 159–161
- peptide nucleic acids *see* PNAs
- peptides
 - fusogenic 47
 - nanoparticles 145–176
 - NLS 27, 43
- peroral administration, body distribution 175
- peroral application, protein-based particles 175
- persistence length, DNA nanotubes 8
- Peyer's patch, electron photomicrograph 383
- PGA *see* polyglycolic acid
- pharmaceutical applications, albumin nanoparticles 198–207
- pharmaceutical current good manufacturing practice (cGMP) 270
- pharmaceutical nanoparticles
 - comminution 265
 - lipid-based 258–259, 263
 - monodisperse 277
- pharmacokinetics
 - gliadin nanoparticles 132
 - ICG 322, 331–336
- phase behavior, lipids 259–261
- phase separation phenomena, nanoparticle preparation 258
- phosphatidylcholine (PC) 352
- phosphatidylethanolamine (PE) 352
- phosphatidylglycerol, liposomes 310
- phosphatidylserine (PS) 352
 - liposomes 310
- photoactive agent, ICG 320
- photodegradation, ICG 326
- photon correlation spectroscopy (PCS), particle size 159
- photoradiation therapy (PDT) 318
- photosensitizer molecules 314
- photosensitizers, PDT 320
- phthalocyanine dyes, fluorescence imaging 318
- physicochemical characteristics, gliadin nanoparticles 133
- PIBCA *see* poly(isobutyl cyanoacrylate)
- PicoGreen assay 92
- pilocarpine, ophthalmic administration 174
- pilocarpine-coated albumin nanoparticles, topical drug delivery 205
- pilocarpine nitrate 195
- pinocytosis 77, 95–96, 358
- plant protein-based nanoparticles 117–137
 - drug encapsulation 124–127
- plant proteins, characteristics 118–120

- plasma protein composition 298
 plasmid DNA, incorporation 155
 plasmids
 – globular assembly 30
 – heat-induced denaturation 42
 – size in comparison to virus and cell 27
 plasmid–transferrin–PNA complex 42
 PLGA, structure 147
 PLGA microspheres, hydrophobic 148
 PLGA nanoparticles, uptake 328
 PNAs 41–42
 – plasmid–transferrin–PNA complex 42
 – size in comparison to natural DNA 42
 poloxamer 338 296
 poly(alkyl cyanoacrylates) 366
 – structure 147
 poly(alkyl methacrylates), structure 147
 poly(amidoamine) dendrimers 307
 poly(D,L lactic-co-glycolic acid) 354
 poly(D,L-lactide-co-glycolide) 312
 poly(isobutyl cyanoacrylate) 366
 poly(N-isopropylacrylamide), polymeric micelles 310
 poly(propylene imine) dendrimers 307
 poly(thioetheramido acid)–PEG copolymer-grafted HSA 194
 poly(vinyl pyrrolidone) 81
 polyacrylamide nanospheres 381
 polycationic ferritin (PCF) 242–243
 polyclonal antibodies 166
 polyethylene glycol *see* PEG
 polyethylene oxide (PEO) 297
 polyethylenimine (PEI) 196
 polyglycolic acid (PGA), structure 147
 polylactic acid, nanoparticle preparation 313
 polylactic-co-glycolic acid *see* PLGA
 polymer-based nanoparticulate delivery, skin 366
 polymer erosion, DNA release 93–94
 polymer nanoparticles, albumin coating 196
 polymeric micelles 310
 polymeric stabilizers 267
 polymers
 – nonbiodegradable 370–371
 – stabilization ability 257
 polymorphous lipoplex 56
 polysaccharide 68
 polysorbate 60 296
 polysorbate 80 372
 polysorbate-coated poly(butyl cyanoacrylate) *see* PBCA
 PPI *see* poly(propylene imine) dendrimers
 precipitation technique, chitosan nanoparticle preparation 94
 preclinical studies, protein-based particles 172
 processability, drug particle size dependence 256
 progesterone, drug delivery system 175
 prolamins, characteristics 118
 protective coat, DNA nanoparticles 43–46
 protein, KNOB 83
 protein-based microspheres, immunological reactions 175–177
 protein-based nanomaterials 115–245
 protein-based nanoparticles
 – preparation 120–124
 – surface modifications 164
 protein-based particles
 – clinical studies 172
 – oral delivery 384–385
 – peroral application 175
 – preclinical studies 172
 – topical application 174–175
 protein desolvation 158
 proteins, chimeric 43
 PS *see* phosphatidylserine
 PS60-SLN 296
Pseudomonas aeruginosa 377–378
 psoralen–DNA–peptide conjugate 41
 P–T diagram, pure substance 271
 pure pharmaceutical components, atomization 273
 purification, nanoparticles 154, 191
 PVP (Poly(vinyl pyrrolidone)) 81
 PX338-SLN 296
- q**
 quantum dots 309–310, 362
 quaternization, chitosan amino groups 80
- r**
 RA (all-*trans* retinoic acid, vitamin A) 124–125
 RA encapsulation, gliadin nanoparticles 124–125
 rabbit serum albumin 149
 radioactive tracers 198
 radionuclide ⁶⁷Gd, attachment to nanoparticles 164
 radiopharmaceuticals 198
 rapid expansion of supercritical solution 272–273
 re-dispersibility, dried nanoparticles 269
 reactive groups, albumin microspheres 165
 reactive oxygen species (ROS) 319
 receptor
 – asialoglycoprotein 81–82
 – folic acid 83

- receptor-mediated endocytosis 38
- release kinetics, chitosan nanoparticles 93–95
- remote loading technology, drug trapping 262
- RES 262
- RES uptake, modified chitosans 80
- respiratory syncytial virus infection, gene therapy with chitosan–DNA complex 97
- RESS *see* rapid expansion of supercritical solution
- reticuloendothelial system *see* RES
- retinitis, HCMV 206
- reverse Hoogsteen base pairs 40
- reverse micellar method, chitosan nanoparticle preparation 89
- ribbon structure, DNA nanotubes 10
- ROS *see* reactive oxygen species

- S**
- S-layer fusion proteins 228–240
 - rSbpA_{31a1068} 239
 - rSbpA_{31a1068}/cAb-Lys3 235
 - rSbpA_{31a1068}/cAb-PSA-N7 236
- S-layer lattices, thickness 220
- S-layer proteins
 - archaeae 219
 - bacteria 219
 - immobilization 225–226
 - nanoscale patterning 219–252
 - properties 220–225
 - SbsA 226–227
 - SbsB 227–228
 - SbsC 228–229
 - S-layer homology (SLH) motifs 222
- S-layer reassembly, spatial control 241–241
- S-layer streptadivin *see* streptadivin
- S-layer variation 223
- S-layers
 - carbohydrate-binding 223–224
 - chemistry and molecular biology 221–223
 - formation of regularly arranged nanoparticles 242–244
 - glycoprotein 219
 - glycosylation 221
 - heterogeneous ligand model 223–224
 - isoelectric point 221
 - isolation 220–221
 - monomolecular protein lattices 219
 - nanoparticles on 244–244
 - recrystallization 220–221
 - recrystallization experiments 229
 - symmetry 220
- S-liposomes, S-layer-coated liposomes 239
- “sandwich” phase, lipoplexes 52–54
- SAS *see* supercritical antisolvent
- scanning electron micrograph
 - gliadin nanoparticles 123
 - vicilin nanoparticles 121
- scanning electron microscopy (SEM) 89, 371
- SCF
 - approaches 270–275
 - characteristics 270–271
 - particle formation 271–272
- SCWP
 - biomimetic linkers 224
 - formation from 3 SLH motifs 222
 - secondary cell wall polymer 222
 - thiolated SCWP 224
- secondary cell wall polymer *see* SCWP
- SEDS *see* solution-enhanced dispersion by SCFs
- self-assembled DNA nanotubes 3–22
- self-assembly, DAE-O tiles 9
- self-assembly method, dendrimer synthesis 306
- self-assembly system, nanoscale patterning of S-layer proteins 219–252
- semipermeable nanoporous barrier, skin 363
- serum albumin 187–196
 - three-domain model 187
- SFM
 - heterotetramers 230
 - surface topography of S-layers 220
- side-effects, doxorubicin 368
- sieving method, chitosan nanoparticle preparation 91
- silver nanoparticles, color index 379
- simple coacervation 155–159
- siRNA lipoplexes 62
- site-specific drug delivery, solid lipid nanoparticles 287–303
- skin 363
 - drugs crossing problems 354–357
 - low-voltage electroporation 355–357
 - mechanical irritation 355
- SLH, S-layer homology 222
- SLN *see* solid lipid nanoparticles
- SM *see* sphingomyelin
- small drugs, BBB crossing 359
- small unilamellar vesicles (SUV) 261
- smart nanoparticle probes 370
- sodium alginate–BSA nanoparticles 201
- sodium azide, cytotoxicity of ICG 323
- sodium polyaspartate (PASP), ICG stabilization 326
- sodium sulfate, use in ionic crosslinking 87
- sodium tripolyphosphate (PSTP), use in ionic crosslinking 87
- solid-lipid nanoparticles (SLN) 288, 354

- *in vitro* occlusion 365
 - *in vivo* elasticity 365
 - *in vivo* occlusion 365
 - *in vivo* wrinkles 365
 - biofunctionalized 287–303
 - chemical stability 364
 - production 292–294
 - skin delivery 364
 - UV sunscreen 366
 - solubility
 - chitosan 70
 - effect on chitosan transfection efficiency 79–80
 - solubility parameter of gliadin, Hildebrand theory 123
 - solution-enhanced dispersion by SCFs (SEDS) 274–275
 - nozzle system 274
 - sonochemical method, albumin nanoparticles 193
 - “spaghetti” tubule structures, lipoplexes 57
 - sphingomyelin (SM) 352
 - SPR-spectroscopy, SCWP
 - spray drying, chitosan nanoparticle preparation 88–89
 - stabilization
 - albumin coacervates 191
 - albumin nanoparticles 187
 - ICG 326
 - stabilization ability, polymers 257
 - stabilizers, polymeric 267
 - starburst divergent method, dendrimer synthesis 306
 - starting materials, nanoparticle preparation 146
 - stealth carriers 290
 - stealth liposomes 262
 - sticky ends 5
 - stiffness, DNA nanotubes 8
 - Stokes’ diameter, nanoparticles 159
 - stomach mucosa, bioadhesion of gliadin nanoparticles 132–135
 - storage proteins, characteristics 118
 - streptavidin 229
 - biotin-binding properties 233
 - suicide gene therapy, albumin nanoparticles 203–204
 - sulfo-MBS 168
 - sulfo-SMCC 168
 - sulfosuccinimidyl-4-N-maleimidomethylcyclohexane-1-carboxylate (sulfo-SMCC) 168
 - supercritical antisolvent 273–274
 - supercritical fluids *see* SCF
 - supercritical nanoparticles 270
 - surface energy, drug particles 256
 - surface modification
 - drug-targeting ligands 166
 - functionalization 294–298
 - hydrophilic compounds 164–165
 - polyethylene glycol 165–166
 - protein-based nanoparticles 164
 - strategies 168–169
 - surfactants 295
 - surface plasmon resonance spectroscopy *see* SPR-spectroscopy
 - surfactant–DNA complexes 34
 - biomedical applications 36
 - organization 35
 - stability 35–37
 - ultrastructure 35
 - surfactant–plasmid complexes, morphology 36
 - surfactants
 - cationic 34
 - CTAB 36
 - reverse micellar method 89
 - stabilization ability 257
 - surface modification 295
 - synthesis 31–35
 - SUV *see* small unilamellar vesicles
 - SWNT *see* hemispherical endcaps nanotubes
 - SynB vectors, peptide drug delivery 360
 - synthesis
 - nanoparticles 244–244
 - nucleic acid nanoparticles 27–31
 - surfactants 31–35
- t**
- TAO, DNA structure 4
 - TAPP-Br, drug-loaded gelatin microspheres 152
 - target specific carriers 289
 - TAT protein 373
 - Taxol 173
 - TEM *see* transmission electron microscopy
 - TetR protein, fusion with NLS peptide 43
 - Tf *see* transferrin
 - therapeutic DNA, chemical and physical properties 25–27
 - therapy, magnetically targeted 204
 - thermodegradation, ICG 326
 - thermodynamic approaches, nanoparticle preparation 257–264
 - thiamine-coated delivery, BBB 376
 - thickening agent, albumin emulsification 192
 - three-domain model, serum albumin 187
 - 4 × 4 tile nanotubes 14–15

- 6HB tile nanotubes 16–17
 - TNBS *see* 2,4,6-trinitrobenzenesulfonic acid
 - α -tocopherol (vitamin E, VE) 124–125
 - lipophilic model 126–127
 - toxicity, ICG 322
 - TP *see* triple point
 - trafficking, intracytoplasmic 26–27
 - transbilayer lipid movement 353
 - transfection efficiency
 - chitosan 76
 - DNA nanoparticles 46
 - modified chitosans 79–84
 - unmodified chitosan 71
 - transfection reagents, commercially available 172
 - transferrin (Tf) 38–39, 82, 96, 369
 - plasmid–transferrin–PNA complex 42
 - transmission electron microscopy (TEM)
 - DNA nanotubes 10
 - mass distribution of S-layers 220
 - monomolecular DNA condensation 45
 - trastuzumab 167
 - 2,4,6-trinitrobenzenesulfonic acid, nanoparticle surfaces 168
 - trimethylation, chitosan amino groups 80
 - triple helix formation 41
 - with oligodeoxyribonucleotides 39–41
 - triple point (TP) 270
 - tripolyphosphate, crosslinking agent 258
 - tubules, lipid 264
 - tumor diagnosis 304
 - ICG 320
 - ICG limitations 324–325
 - optical nanoparticles 314–315
 - tumor imaging, ICG 322–323
 - tumor necrosis factor- α , secretion in presence of nanoparticles 73
 - tumor tissue, lipofection 60
 - tumor treatment
 - ICG 320
 - ICG limitations 324–325
 - optical nanoparticles 315–316
 - TX tile nanotubes 11–13
 - metallization 11
- u**
- UA (urocanic acid), coupled with water-soluble chitosan 78
 - ultrastructure, surfactant–DNA complexes 35
 - unmodified chitosan, schematic gene therapy mechanism 79
 - uptake by tumors, ICG 325
 - urocanic acid (UA), coupled with water-soluble chitosan 78
 - urokinase 195
 - UV sunscreen, solid-lipid nanoparticles 366
- v**
- K_d values 224
 - variable domain, light chain antibody 235
 - VE (α -tocopherol, vitamin E) 124–125
 - lipophilic model 126–127
 - VE encapsulation, gliadin nanoparticles 125–126
 - vectors
 - multicomponent delivery 47
 - viral 170
 - vegetable albumins, characteristics 118
 - VH 235
 - VHH, antibody isotype 233
 - vicilin, pea seed proteins 119
 - vicilin nanoparticles
 - preparation 121–122
 - scanning electron micrograph 121
 - viral vectors, gene therapy 51
 - virus infection, respiratory syncytial 97
 - vitamin A (all-*trans* retinoic acid, RA) 124–125
 - vitamin E (α -tocopherol, VE) 124–125
 - lipophilic model 126–127
 - VL 235
- w**
- w/o *see* water-in-oil emulsion
 - water-in-oil emulsion (w/o) 87
 - water-soluble chitosan 78
 - water soluble polymers 258
 - Watson, J. D. 23
 - weakly overlapping mushroom regime, DNA nanoparticle protection 45
 - wet comminution 266–267
 - wheat proteins 119–120
 - wrapping vector 10
- y**
- yield, nanoparticles 191
 - YOYO, intercalating dye 36, 46
- z**
- zona pellucida (ZP) 98
 - ZP *see* zona pellucida